References
- Moccia M, Brigo F, Tedeschi G, Bonavita S, Lavorgna L. Neurology and the Internet: a review. Neurol Sci. 2018;39:981–7.
- SPGolbal [online]. Available at: https://www.spglobal.com/marketintelligence/en/news-insights/trending/fP4S2NeWVtd2RvsUElgDYg2. Accessed April 16, 2020.
- The ALSUntangled Group. ALSUntangled 14: Mototab. Amyotroph Lateral Scler. 2012;13:161–4.
- Scientific American [online]. Available at: http://www.scientificamerican.com/article/how-anecdotal-evidence-can-undermine-scientific-results/. Access April 16, 2020.
- Berkowitz A, Miller M, Mir S, Cagney D, Chavakula V, Guleria I, et. al. Glioproliferative lesion of the spinal cord as a complication of “Stem-Cell Tourism”. N Engl J Med. 2016;375:196–8.
- Bedlack R, Pastula D, Welsh E, Pulley D, Cudkowicz M. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler. 2008;9:257–65.
- Bedlack R, Hardiman O. ALSUntangled (ALSU): a scientific approach to off-label treatment options for people with ALS using tweets and twitters. Amyotroph Lateral Scler. 2009;10:129–30.
- ALSUntangled [online]. Available at: http://www.alsuntangled.com/open.php. Accessed April 16, 2020.
- The ALSUntangled Group. ALSUntangled: introducing the table of evidence. Amyotroph Lateral Scler. 2015;16:142–5.
- ALSUntangled [online]. Available at: http://www.alsuntangled.com/completed.html. Accessed April 16, 2020.
- CReATe Consortium [online]. Available at: https://www.spreaker.com/show/create-podcast. Accessed April 16, 2020.
- Conslancio [online]. Available at: http://www.conslancio.it/alsuntangled-podcasts-italiano/. Accessed April 16, 2020.
- Duke Neurology [online]. Available at: https://neurology.duke.edu/about/news/highlights-aan-brainstorm-award-parkinsons-and-exercise-ulysses-s-grants-headaches-and. Accessed April 16, 2020.
- The ALSUntangled Group. ALSUntangled 5: Investigating the Stowe/Morales ALS Protocol. Amyotroph Lateral Scler. 2010;11:414–6.
- CBS News [online]. Available at: https://www.cbsnews.com/news/21st-century-snake-oil-16-04-2010/. Accessed April 16, 2020.
- U.S. Attorney’s Office for the Southern District of Texas [online]. Available at: https://www.justice.gov/usao-sdtx/pr/illegal-sale-stem-cell-case-lands-engineer-federal-prison. Accessed April 17, 2020.
- FDA [online]. Available at: https://www.fda.gov/media/85682/download. Accessed April 16, 2020.
- Lind S. Fee for service research. N Engl J Med. 1986;314:312–5.
- Chan S. Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation. Regen Med. 2017;12:839–51.
- Bee Well Therapy [online]. Available from: http://www.beewelltherapy.com/. Accessed April 16, 2020.
- Armon C. Ethics of clinical research in patients with ALS: is there a risk of exploitation? Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:161–6.
- FDA Website [online]. Available at: https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application. Accessed August 21, 2019.
- Smithsonian Magazine [online]. Available at: https://www.smithsonianmag.com/science-nature/woman-who-stood-between-america-and-epidemic-birth-defects-180963165/. Accessed August 21, 2019.
- The ALSUntangled Group. ALSUntangled Update 3: investigating stem cell transplants at the hospital san jose tecnologico de monterrey. Amyotroph Lateral Scler. 2010;11:250–2.
- Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009;11:26–34.
- Nelson-Marten P, Rich B. A historical perspective of informed consent in clinical practice and research. Semin Oncol Nurs. 1999;15:81–8.
- Benbrika S, Desgranges B, Eustache F, Viader F. Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: a review. Frontiers in Neurosci. 2019;13:951.
- The ALSUntangled Group. ALSUntangled 6: Investigating Marty Murray’s Method. Amyotroph Lateral Scler. 2010;11:494–6.
- The ALSUntrangled Group. ALSUntangled 12: Dean Kraft, Energy Healter. Amyotroph Lateral Scler. 2011;12:389–91.
- The ALSUntrangled Group. ALSUntangled 19: Sodium Chlorite. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:236–8.
- The ALSUntangled Group. ALSUntangled 27: Precision Stem Cell. Amyotroph Lateral Scler Frontotemporal Degener. 2015;27:282–5.
- Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et. al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
- Castrillo-Viguera C, Grasso D, Simpson E, Shefner J, Cudkowicz M. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord.2010;11:178–80.
- Gordon PH, Miller R, Moore D. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord.2004;5:90–3.
- Kaufmann P, QALS study group, Levy G, Montes J, Buchsbaum R, Barsdorf A, Battista V, et. al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial . Amyotroph Lateral Scler. 2007;8:42–6.
- Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon P, et al. Development and evaluation of a self-administered version of the ALSFRS-R. Neurology 2006;67:1294–6.
- Bedlack R, Wicks P, Vaughan T, Opie A, Blum R, Dios A, et al. Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial . Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:285–93.
- Fournier C, Bedlack R, Quinn C, Russell J, Beckwith D, Kaminski K, et. al. Development and validation of the rasch-built overall amyotrophic lateral sclerosis disability score (ROADS). JAMA Neurol. 2020;77:480.
- The ALSUntangled Group. ALSUntangled 4: Investigating the XCell-Center. Amyotroph Lateral Scler Frontotemporal Degener. 2010;1:337–8.
- Pozgain I, Pozgain Z, Degmecic D. Placebo and nocebo effect: a mini-review. Psychiatr Danub 2014;26:100–7.
- Altman DG. Poor-Quality Medical research: what can journals do? JAMA 2002;287:2765–7.
- Kelly J, Sadeghieh T, Adeli K. Peer review in scientific publications: benefits, critiques, & a survival guide. EJIFCC 2014;25:227–43.
- New York Times [online]. Available at: https://www.nytimes.com/2009/07/15/technology/internet/15lift.html?_r=2. Accessed April 13, 2020.
- Bedlack R, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et. al. How common are ALS plateaus and reversals? Neurology. 2016;86:808–12.
- The ALSUntangled Group. ALSUntangled 20: The Deanna Protocol. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:319–23.
- The ALSUntangled Group. ALSUntangled 34: GM604. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:7–8.
- The ALSUntangled Group. ALSUntangled 36: Accilion. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:142–7.
- The ALSUntangled Group. ALSUntangled 17: “When ALS Is Lyme”. Amyotroph Lateral Scler. 2012;13:487–9.
- Lynes B. The cancer cure that worked! South Lake Tahoe, CA: BioMed Publishing Group; 1987.
- The ALSUntangled Group. ALSUntangled 51: “RCH4”. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:150–3.
- Wikipedia [online]. Available at: https://en.wikipedia.org/wiki/Scientific_method. Accessed April 16, 2020.
- The ALSUntangled Group. ALSUntangled 41: “Eric is Winning”. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:157–60.
- Eric is Winning by Eric Edney. Copyright 2006 bu Xlibris, USA.
- EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS Guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.